RegeneRx Biopharmaceuticals, Inc. yana ba da rahoto cewa masu bincike sun nuna tasirin maganin Thymosin Beta 4 (Tβ4) a matsayin haɗin haɗin gwiwa tare da hyperglycemia (mai ciwon sukari) - canje-canjen da aka haifar a cikin ƙwayoyin epithelial na corneal na mutum.
"Binciken mu ya bayyana a karon farko cewa Tβ4 da vasoactive intestinal peptide (VIP) magani hade suna taka muhimmiyar rawa wajen daidaita daidaiton kwanciyar hankali da sake tsara cytoskeleton [na cornea], waɗanda ke da alaƙa da alaƙa da amincin shinge. Bugu da ƙari kuma, Tβ4 yana da ƙarfi ya kafa matsayinsa a matsayin magani mai mahimmanci don cututtukan ƙwayar cuta na ciwon sukari ba tare da wani sakamako mai illa ba, ta haka yana sauƙaƙe rashin lahani na hanyoyin kulawa na yanzu, "a cewar ƙungiyar binciken.
An gabatar da binciken a Ƙungiyar Bincike a cikin Vision da Ophthalmology (ARVO) 2022 taron, wanda aka gudanar a watan Mayu 1-4, 2022, a Denver, Colorado. Ƙungiyar binciken ta haɗa da masana kimiyya da likitoci daga Makarantar Medicine na Jami'ar Wayne a Detroit, MI; Jami'ar Central Florida College of Health Professors and Sciences a Orlando, FL; da Jami'ar Mansoura a Mansoura, Masar. Cibiyar Kula da Lafiya ta Kasa ce ta dauki nauyin binciken, Cibiyar ta Eversight don Binciken hangen nesa da Bankin Ido, da Bincike don Hana Makanta.
